

Status: Currently Official on 15-Feb-2025  
 Official Date: Official as of 01-May-2022  
 Document Type: USP Monographs  
 DocId: GUID-FC1EDFC5-7834-457E-ABAC-717F4DB5A3D4\_2\_en-US  
 DOI: https://doi.org/10.31003/USPNF\_M36010\_02\_01  
 DOI Ref: jp2k1

© 2025 USPC  
 Do not distribute

## Guaifenesin Oral Solution

### DEFINITION

Guaifenesin Oral Solution contains NLT 90.0% and NMT 110.0% of the labeled amount of guaifenesin ( $C_{10}H_{14}O_4$ ).

### IDENTIFICATION

#### Change to read:

• **A.** (USP 1-May-2022) The retention time of the guaifenesin peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

#### Add the following:

• **B.** The UV spectrum of the guaifenesin peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay. (USP 1-May-2022)

### ASSAY

#### Change to read:

##### PROCEDURE

**Mobile phase:** [Methanol](#), [glacial acetic acid](#), and [water](#) (40: 1.5: 60)

**Benzoic acid solution:** 2 mg/mL of [benzoic acid](#) in [methanol](#)

**Standard stock solution:** 2 mg/mL of [USP Guaifenesin RS](#) in [water](#). Shake to dissolve.

**Standard solution:** 40 µg/mL of [USP Guaifenesin RS](#) prepared as follows. Transfer 2.0 mL of the *Standard stock solution* to a 100-mL volumetric flask. Add 45 mL of [methanol](#) and dilute with [water](#) to volume.

**System suitability solution:** 100 µg/mL of benzoic acid and 40 µg/mL of [USP Guaifenesin RS](#) prepared as follows. Transfer 5.0 mL of *Benzoic acid solution* and 2.0 mL of *Standard stock solution* to a 100-mL volumetric flask. Add 40 mL of [methanol](#) and dilute with [water](#) to volume.

**Sample stock solution:** Nominally 2 mg/mL of guaifenesin from Oral Solution in water prepared as follows. Transfer a suitable volume of Oral Solution, equivalent to 200 mg of guaifenesin, to a 100-mL volumetric flask. Dilute with [water](#) to volume

**Sample solution:** Nominally 40 µg/mL of guaifenesin prepared as follows. Transfer 2.0 mL of the *Sample stock solution* to a 100-mL volumetric flask. Add 45 mL of [methanol](#) and dilute with [water](#) to volume.

#### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 276 nm. <sup>▲</sup>For *Identification B*, use a diode array detector in the range of 200–400 nm. <sup>▲</sup>(USP 1-May-2022)

**Column:** 4.6-mm × 25-cm; 10-µm packing [L1](#)

**Flow rate:** 2 mL/min

**Injection volume:** 20 µL

#### System suitability

**Samples:** *Standard solution* and *System suitability solution*

[NOTE—The relative retention times for guaifenesin and benzoic acid are 0.7 and 1.0, respectively.]

#### Suitability requirements

**Resolution:** NLT 3.0 between guaifenesin and benzoic acid, *System suitability solution*

**Relative standard deviation:** NMT <sup>▲</sup>1.0%, <sup>▲</sup>(USP 1-May-2022) *Standard solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of labeled amount of guaifenesin ( $C_{10}H_{14}O_4$ ) in the portion of Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of guaifenesin from the *Sample solution*

$r_S$  = peak response of guaifenesin from the *Standard solution*

$C_S$  = concentration of [USP Guaifenesin RS](#) in the *Standard solution* (µg/mL)

$C_U$  = nominal concentration of guaifenesin in the *Sample solution* (µg/mL)

**Acceptance criteria:** 90.0%–110.0%

#### OTHER COMPONENTS

- [ALCOHOL DETERMINATION \(611\), Method I](#): (if present) 90.0–115.0% of the labeled amount of alcohol (C<sub>2</sub>H<sub>5</sub>OH)

#### PERFORMANCE TESTS

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#)

**For Oral Solution packaged in single-unit containers:** Meets the requirements

- [DELIVERABLE VOLUME \(698\)](#)

**For Oral Solution packaged in multiple-unit containers:** Meets the requirements

#### SPECIFIC TESTS

**Change to read:**

- [pH \(791\)](#): 2.3–<sup>▲</sup>6.5<sup>▲</sup> (USP 1-May-2022)

#### ADDITIONAL REQUIREMENTS

**Change to read:**

- **PACKAGING AND STORAGE:** Preserve in tight containers. <sup>▲</sup>Do not refrigerate.<sup>▲</sup> (USP 1-May-2022)
- [USP REFERENCE STANDARDS \(11\)](#)  
[USP Guaifenesin RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question            | Contact                                       | Expert Committee          |
|---------------------------|-----------------------------------------------|---------------------------|
| GUAIFENESIN ORAL SOLUTION | <a href="#">Documentary Standards Support</a> | SM22020 Small Molecules 2 |

**Chromatographic Database Information:** [Chromatographic Database](#)

#### Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 46(5)

**Current DocID:** GUID-FC1EDFC5-7834-457E-ABAC-717F4DB5A3D4\_2\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M36010\\_02\\_01](https://doi.org/10.31003/USPNF_M36010_02_01)

**DOI ref:** [jp2k1](#)